clinical trial · NCT06902246
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
University of Miami·phase2·recruiting·n = 30
Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaRegorafenibTheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
brief summary
The purpose of this study is to determine the effects that Regorafenib in combination with Yttrium-90 (Y-90) radioembolization has on patients with unresectable hepatocellular carcinoma.
started
May 1, 2026
primary completion
May 1, 2031
completion
May 1, 2031
last updated
Mar 27, 2026
official title
Regorafenib and Yttrium-90 Radioembolization for Treatment of Unresectable Hepatocellular Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol